Correction to: Indacaterol: a new long-acting β2-agonist in the management of chronic obstructive pulmonary disease
Steiropoulos P, Papanas N, Nena E, et al. Indacaterol: a new long-acting β2-agonist in the management of chronic obstructive pulmonary disease Expert Opin Pharmacother 2012:13(7):1015-29
Following publication of this article, an error has been identified in the second paragraph of section 3.3.1. The dosage is mentioned as 140 ml instead of 40 ml. The corrected paragraph is:
In their dose-finding study, Barnes et al. Citation[27] reported that all indacaterol doses (75, 150, 300, 600 μg) produced higher differences in trough FEV1 and FEV1 – AUC(1 - 4 h) as compared to placebo than did open-label tiotropium; while at the same time, indacaterol doses (150 or 300 μg) increased trough FEV1 vs tiotropium at week 12 by 40 ml, as Donohue et al. Citation[30] demonstrated.
References
- Barnes PJ, Pocock SJ, Magnussen H, Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design. Pulm Pharmacol Ther 2010;23:165-71
- Donohue JF, Fogarty C, Lotvall J, Once daily bronchodilators for chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010;182:155-62